{
  "pmcid": "12283117",
  "sha256": "da6a79389c524fed18b094ef47c2c5088808605e711ad5eb93a4b298ab16f7f9",
  "timestamp_utc": "2025-11-09T23:32:15.957448+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.079824380165288,
    "reading_ease": 28.22610020661159,
    "word_count": 242
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial Comparing Recurrence Rates of Diabetic Foot Ulcers and Chronic Limb-Threatening Ischaemia to Advanced-Stage Cancers"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Inclusion criteria included prospective studies and randomised clinical trials."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the 3-year recurrence rates of diabetic foot ulcers (DFU) and the rate of endovascular reintervention for chronic limb-threatening ischaemia (CLTI) to recurrence rates of advanced-stage cancers."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 3-year recurrence rate."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The pooled 3-year DFU recurrence rate was 58%, while the CLTI reintervention rate was 50%. These rates are comparable to cancer recurrence rates: breast (25%-40%), prostate (30%-40%), colorectal (30%-50%), and lung (60%-80%)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Harm: Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not provided."
      }
    },
    "total_score": 7,
    "max_score": 25
  }
}